tiprankstipranks
Trending News
More News >
Polynovo Limited (AU:PNV)
ASX:PNV
Advertisement

Polynovo (PNV) AI Stock Analysis

Compare
67 Followers

Top Page

AU:PNV

Polynovo

(Sydney:PNV)

Rating:59Neutral
Price Target:
AU$1.50
▲(13.64%Upside)
Polynovo Limited's overall stock score reflects strong financial growth and stability, contrasted by technical analysis indicators suggesting mixed market sentiment. The high valuation poses a risk, as the P/E ratio is significantly higher than average. The absence of earnings call data and corporate events means these factors did not influence the score.

Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)

Polynovo Business Overview & Revenue Model

Company DescriptionPolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
How the Company Makes MoneyPolyNovo makes money primarily through the sale of its NovoSorb technology-based products. The company's revenue model is centered on manufacturing and distributing its proprietary medical devices to hospitals, clinics, and healthcare professionals globally. Key revenue streams include the sale of NovoSorb BTM (Biodegradable Temporizing Matrix), which is used for dermal regeneration in complex wound treatments. PolyNovo also establishes partnerships and distribution agreements with healthcare providers and medical distributors to expand its market reach and enhance product accessibility. Additionally, the company may engage in research collaborations and licensing agreements to further capitalize on its proprietary polymer technology, contributing to its earnings.

Polynovo Financial Statement Overview

Summary
Polynovo Limited exhibits promising financial growth with strong revenue increase and a return to profitability. The company maintains a solid equity position and improved cash flow metrics, although there is room for better operational efficiencies and conversion of net income to cash flow.
Income Statement
75
Positive
Polynovo Limited has shown strong revenue growth with a notable increase from $65.24M in 2023 to $103.19M in 2024. The company turned profitable with a net income of $5.26M in 2024, demonstrating a positive net profit margin. The gross profit margin improved significantly, indicative of better cost management. However, the EBIT and EBITDA margins, although improved, remain relatively low, suggesting room for operational efficiency improvements.
Balance Sheet
68
Positive
The company maintains a solid equity position with a strong equity ratio of approximately 66.36% in 2024, which indicates financial stability. The debt-to-equity ratio decreased over the years, reflecting prudent financial management. However, the return on equity is moderate, suggesting that while the company is financially stable, it could improve its efficiency in generating profits from its equity base.
Cash Flow
62
Positive
Polynovo's cash flow situation has improved, with a positive operating cash flow of $3.68M in 2024 compared to negative figures in previous years. Free cash flow turned positive, indicating better cash management. However, the free cash flow to net income ratio is relatively low, suggesting that the conversion of net income to free cash flow could be enhanced.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue103.19M65.24M41.44M29.16M22.16M
Gross Profit97.71M19.33M16.23M7.83M5.01M
EBITDA4.05M-2.71M658.24K-3.41M-3.27M
Net Income5.26M-4.92M-1.19M-4.61M-4.19M
Balance Sheet
Total Assets108.72M92.62M34.97M38.34M37.86M
Cash, Cash Equivalents and Short-Term Investments45.96M46.90M6.15M7.74M11.70M
Total Debt15.38M16.04M10.99M10.00M10.03M
Total Liabilities36.60M27.24M17.26M15.99M14.04M
Stockholders Equity72.12M65.38M17.72M22.35M23.81M
Cash Flow
Free Cash Flow786.00K-7.46M-2.55M-3.82M-9.27M
Operating Cash Flow3.68M-5.93M-2.06M-248.74K-402.56K
Investing Cash Flow-1.49M-1.53M5.86M-3.57M-8.87M
Financing Cash Flow-3.17M48.06M-5.39M-70.37K7.03M

Polynovo Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.32
Price Trends
50DMA
1.25
Positive
100DMA
1.24
Positive
200DMA
1.66
Negative
Market Momentum
MACD
0.01
Negative
RSI
65.78
Neutral
STOCH
87.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PNV, the sentiment is Positive. The current price of 1.32 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.25, and below the 200-day MA of 1.66, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 65.78 is Neutral, neither overbought nor oversold. The STOCH value of 87.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PNV.

Polynovo Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$887.73M149.428.30%39.19%273.91%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
$98.22M-15.86%
61
Neutral
AU$193.22M-4.06%20.36%64.81%
49
Neutral
AU$148.37M-58.61%-74.88%
45
Neutral
AU$117.81M-35.20%4.68%-155.42%
41
Neutral
AU$116.39M-52.37%471.29%-4.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:PNV
Polynovo
1.33
-1.26
-48.64%
SOMNF
Somnomed Limited
0.46
0.22
91.67%
AU:CYC
Cyclopharm Limited
1.06
-0.54
-33.75%
AU:ARX
Aroa Biosurgery Ltd
0.59
-0.04
-6.35%
AU:EMV
EMvision Medical Devices Ltd.
1.73
-0.26
-13.07%
AU:4DX
4DMedical Ltd
0.26
-0.26
-50.00%

Polynovo Corporate Events

PolyNovo’s NovoSorb BTM Achieves Breakthrough in Islet Cell Transplant
Jul 15, 2025

PolyNovo announced a special briefing featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb BTM in a groundbreaking islet cell transplant for a Type 1 diabetic patient. This development highlights NovoSorb’s versatility and potential to enter new markets, reinforcing PolyNovo’s innovative position in the medical technology industry.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo’s NovoSorb Expands into Islet Cell Transplant Market
Jul 14, 2025

PolyNovo announced a special briefing hosted by Bell Potter featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb in a pancreatic islet transplant for a long-term Type 1 diabetic. This marks a new market entry for NovoSorb, showcasing its versatility and potential impact on the medical field, particularly in islet cell transplantation.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

Polynovo Announces Changes in Shareholder Structure
May 21, 2025

Polynovo Limited has announced a significant change in its shareholder structure, with various entities, including State Street Bank and Trust Company and its subsidiaries, becoming substantial holders. This development indicates a shift in the company’s ownership dynamics, potentially impacting its strategic decisions and market positioning. The involvement of major financial institutions as substantial holders could influence Polynovo’s future operations and stakeholder engagements.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo Releases May 2025 Investor Update Webcast Recording
May 16, 2025

PolyNovo has released a recording of its May 2025 Investor Update Webcast for shareholders and interested parties who missed the live event. This announcement underscores PolyNovo’s commitment to transparency and stakeholder engagement, potentially strengthening its market position and investor relations.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo’s NovoSorb BTM Shows Breakthrough Results in Type 1 Diabetes Cell Therapy
May 13, 2025

PolyNovo announced positive results from a ‘first in human’ study using its NovoSorb BTM technology for cell therapies in treating Type 1 diabetes. The study, presented by Professor Toby Coates, demonstrated the survival and function of human pancreatic islets transplanted into a new site within the skin, offering a promising alternative to the current standard of care. This breakthrough suggests significant potential for NovoSorb in the cell therapy market, potentially creating a new business segment for PolyNovo. The company is in discussions to accelerate research and development in this space, which is projected to reach USD $34 billion by 2034.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo Secures TGA Clearance for NovoSorb MTX in Australia
May 12, 2025

PolyNovo Limited has achieved a significant commercial milestone with the Therapeutic Goods Administration (TGA) clearance of its NovoSorb MTX (4 mm and 6 mm) products in Australia. This clearance allows the products to be marketed and sold, providing healthcare professionals with versatile options for managing soft tissue defects. The NovoSorb MTX is designed to support natural wound healing, particularly for highly exudative wounds or those with uneven wound beds, and addresses clinician demand for products without a sealing membrane. This development enhances PolyNovo’s industry positioning by expanding its product offerings and meeting the needs of plastic surgeons and other healthcare providers.

PolyNovo Highlights Strategic Focus at Macquarie Australia Conference
May 7, 2025

PolyNovo Limited’s presentation at the Macquarie Australia Conference highlights the company’s ongoing commitment to innovation in wound care technology. While the presentation includes forward-looking statements subject to change, it underscores the company’s strategic focus on expanding its market presence and enhancing its product offerings, which could have significant implications for its stakeholders.

PolyNovo to Host Investor Update on Strategic Growth and Financial Outlook
May 1, 2025

PolyNovo Limited announced an upcoming investor update webcast scheduled for May 16, where it will discuss its financial performance, future outlook, cash and capital adequacy, and growth strategies, including market expansion into China and Japan and the launch of NovoSorb MTX. This update is significant for stakeholders as it highlights PolyNovo’s strategic initiatives to enhance its market position and expand its product offerings, potentially impacting its operations and industry standing.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 18, 2025